Company news
Curis, Inc. (NASDAQ:CRIS) news
Curis, Inc. news releases on 6ix. Latest, Nov 2, 2022: Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022
Press releases — page 2
Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022
November 1, 2022
Curis Announces Date for the 1st Symposium on IRAK4 in Cancer
October 2, 2022
Curis Announces Date for the 2nd Annual VISTA Symposium
September 18, 2022
FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study
August 29, 2022
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
August 17, 2022
Curis Reports Second Quarter 2022 Financial Results and Business Update
August 3, 2022
Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 28, 2022
Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022
July 27, 2022
Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress
June 9, 2022
Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)
June 3, 2022
Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)
May 11, 2022
Curis Reports First Quarter 2022 Financial Results and Business Update
May 4, 2022
Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)
April 10, 2022
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)
April 3, 2022
Curis Reports Fourth Quarter and Year End 2021 Financial Results
February 23, 2022
Curis to Release Fourth Quarter 2021 Financial Results and Hold Conference Call on February 24, 2022
February 16, 2022
Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with...
January 5, 2022
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations
January 2, 2022
Curis Appoints John A. Hohneker, M.D. To Board Of Directors
December 5, 2021
Curis Reports Third Quarter 2021 Financial Results and Business Update
November 8, 2021
Curis Announces New Preclinical Data for CI-8993 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 8, 2021
Curis Announces First Patient Dosed in Phase 1/2 Study of CA-4948 Combination Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
November 7, 2021
Curis to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 9, 2021
November 1, 2021
Curis Announces New Preclinical Data Highlighting the Potential of CA-4948 in Multiple Hematologic Malignancies Presented at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics
October 6, 2021
Curis Reports Second Quarter 2021 Financial Results
August 2, 2021
Curis to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 3, 2021
July 26, 2021
Curis, Inc. Set to Join Russell 2000®, 3000® and Microcap® Indexes
June 24, 2021
Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
June 10, 2021
Curis, Inc. Announces 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond"
May 31, 2021
Curis Reports First Quarter 2021 Financial Results
May 11, 2021
Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021
May 4, 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
April 18, 2021
Curis Reports Fourth Quarter and Year-End 2020 Financial Results
March 15, 2021
Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting
March 9, 2021
Curis to Release Fourth Quarter 2020 Financial Results and Hold Conference Call on March 16, 2021
March 8, 2021
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies
February 8, 2021
Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes
February 1, 2021
Curis Announces Closing of Public Offering of Common Stock with $169.6 Million in Gross Proceeds, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
December 13, 2020
Curis Announces Pricing of Public Offering of Common Stock
December 8, 2020
Curis Announces Proposed Public Offering of Common Stock
December 7, 2020
Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
December 7, 2020
Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
December 6, 2020
Curis Reports Third Quarter 2020 Financial Results
November 9, 2020
Curis Announces Collaboration with the National Cancer Institute for the Development of IRAK4 Inhibitor, CA-4948, as an Anti-Cancer Agent
November 9, 2020
Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition
November 3, 2020
Curis Reports Second Quarter 2020 Financial Results
August 3, 2020
Curis to Release Second Quarter 2020 Financial Results and Hold Conference Call on August 4, 2020
July 27, 2020
Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
July 6, 2020
Curis Announces $17.5 Million Registered Direct Offering
June 10, 2020
Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody
June 9, 2020